13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001389933
Total reported value
$524.4M
$524.4M
72 檔
26.9%
As reported in its official Q1 2024 Form 13F filing, DAFNA Capital Management LLC's tracked investment portfolio stood at $524.4M with 72 total positions.
During Q1 2024, DAFNA Capital Management LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 9.31% | -3.32% | -10.91% | |
| 2 | STXS | Stereotaxis Inc | Stock-Other | 8.13% | -1.24% | — | |
| 3 | CYTK | Cytokinetics Inc | Stock-Healthcare | 6.35% | -0.47% | -0.47% | |
| 4 | IDYA | Ideaya Biosciences Inc | Stock-Other | 4.46% | -0.08% | -13.56% | |
| 5 | ✓ | Merus N V | Stock-Other | 3.89% | — | -16.68% | |
| 6 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 3.76% | +7.24% | — | |
| 7 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 3.62% | — | -21.80% | |
| 8 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 3.57% | +0.24% | -11.18% | |
| 9 | IBB | Ishares Biotechnology ETF | ETF-Tech | 3.20% | -0.85% | — | |
| 10 | ASND | Ascendis Pharma A/S | Stock-Other | 3.18% | -1.21% | EXIT | |
| 11 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 2.68% | -0.43% | -1.08% | |
| 12 | DAWNGBX | Day One Biopharmaceuticals I | Stock-Other | 2.51% | -4.77% | EXIT | |
| 13 | 2655787D | Blueprint Medicines CORP | Stock-Other | 2.31% | — | -3.70% | |
| 14 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 2.25% | -0.26% | -1.38% | |
| 15 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 2.18% | -1.22% | EXIT | |
| 16 | TNDM | Tandem Diabetes Care Inc | Stock-Other | 2.08% | -0.53% | +16.99% | |
| 17 | DXCM | Dexcom Inc | Stock-Healthcare | 2.07% | -0.12% | -2.96% | |
| 18 | KURA | Kura Oncology Inc | Stock-Other | 2.00% | -0.19% | -16.24% | |
| 19 | ATRC | Atricure Inc | Stock-Other | 1.88% | -0.69% | +115.91% | |
| 20 | MORFUSD | Morphic Holding Inc | Stock-Other | 1.86% | — | — | |
| 21 | AXGN | Axogen Inc | Stock-Other | 1.72% | -0.04% | — | |
| 22 | BHVN | Biohaven Ltd. | Stock-Other | 1.48% | -1.24% | -29.65% | |
| 23 | TSVT* | 2seventy Bio Inc | Stock-Other | 1.47% | — | -16.82% | |
| 24 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 1.27% | +0.96% | -31.86% | |
| 25 | ALEC | Alector Inc | Stock-Other | 1.25% | -0.09% | +49.68% | |
| 26 | IPSC | Century Therapeutics Inc | Stock-Other | 1.24% | -0.13% | — | |
| 27 | LRMR | Larimar Therapeutics Inc | Stock-Other | 1.13% | -0.91% | +102.66% | |
| 28 | ASND 2.25 04-01-28Bond | Ascendis Pharma A/s | Bond | 1.05% | -1.35% | EXIT | |
| 29 | KROS | Keros Therapeutics Inc | Stock-Other | 1.02% | — | -8.88% | |
| 30 | RCUS | Arcus Biosciences Inc | Stock-Other | 1.00% | +0.42% | -0.43% | |
| 31 | LKFT | Lakefront Biotherapeutic-adr | Stock-Other | 0.95% | -0.15% | — | |
| 32 | ISREUR | Isoray Inc | Stock-Other | 0.84% | — | — | |
| 33 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 0.82% | -0.17% | — | |
| 34 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 0.72% | — | -50.28% | |
| 35 | RGLS | Regulus Therapeutics Inc | Stock-Other | 0.70% | — | -3.65% | |
| 36 | BCYC | Bicycle Therapeutics Plc-adr | Stock-Other | 0.69% | -0.02% | — | |
| 37 | ARAY | Accuray Inc | Stock-Other | 0.69% | -0.07% | — | |
| 38 | PODD | Insulet CORP | Stock-Healthcare | 0.62% | +1.28% | — | |
| 39 | PRCT | Procept Biorobotics CORP | Stock-Other | 0.62% | -0.16% | -13.12% | |
| 40 | ✓ | Mediwound LTD | Stock-Other | 0.61% | -0.09% | -26.74% | |
| 41 | SPRY | Ars Pharmaceuticals Inc | Stock-Other | 0.56% | — | -23.13% | |
| 42 | AQST | Aquestive Therapeutics Inc | Stock-Other | 0.48% | +0.16% | — | |
| 43 | ✓ | Proqr Therapeutics N.v. | Stock-Other | 0.47% | -0.04% | -3.72% | |
| 44 | CMPS | Compass Pathways PLC | Stock-Other | 0.46% | +2.39% | +26.02% | |
| 45 | LCTX | Lineage Cell Therapeutics In | Stock-Other | 0.46% | — | — | |
| 46 | STOK | Stoke Therapeutics Inc | Stock-Other | 0.45% | -0.15% | — | |
| 47 | STRO | Sutro Biopharma, Inc. | Stock-Other | 0.43% | — | +18.02% | |
| 48 | INGN | Inogen Inc | Stock-Other | 0.38% | -0.15% | +1291.93% | |
| 49 | GOSS | Gossamer Bio Inc | Stock-Other | 0.38% | — | -4.52% | |
| 50 | BWAY | Brainsway Ltd-adr | Stock-Other | 0.36% | — | -3.51% |
According to official SEC Form 13F filings, DAFNA Capital Management LLC reported a total U.S. public equity portfolio value of $524.4M across 72 disclosed positions in Q1 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including XBI, STXS, CYTK) accounted for 26.9% of total reported equity market value during Q1 2024.
During Q1 2024, DAFNA Capital Management LLC's top holdings by market value included XBI (9.3%)、STXS (8.1%)、CYTK (6.3%). The largest single position, XBI, represented 9.3% of total portfolio value.
In Q1 2024, DAFNA Capital Management LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.